Innovation Pharmaceuticals Inc (IPIX)

[TOB]

Excellent observation sir. With Kevetrin already above the range Dr Menon expected to be therapeutic, the odds of efficacy can only increase with the increasing possible Maximum Tolerated Dose.

No question a still higher cohort dose should be a potential catalyst for increased investor confidence. It certainly will increase my confidence in Kevetrin showing a positive secondary endpoint of efficacy in this trial.

I believe a positive primary outcome measure is all but certain at this point, and we already have reports of stabilization of patients at far lower doses (Stable disease).

With the current focus on the potential blockbuster Brilacidin, it is pretty amazing that CTIX has Kevetrin as well. I sometimes forget that I bought CTIX for Kevetrin with Prurisol as the safety net now that Brilacidin is here with a positive Phase 2b result.